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strain. Their findings reveal that
mismatched mitochondria can be
sufficient to elicit an allogeneic response.
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The generation of pluripotent stem cells by somatic
cell nuclear transfer (SCNT) has recently been
achieved in human cells and sparked new interest
in this technology. The authors reporting this
methodical breakthrough speculated that SCNT
would allow the creation of patient-matched embry-
onic stem cells, even in patients with hereditary
mitochondrial diseases. However, herein we show
that mismatched mitochondria in nuclear-transfer-
derived embryonic stem cells (NT-ESCs) possess
alloantigenicity and are subject to immune rejection.
In a murine transplantation setup, we demonstrate
that allogeneic mitochondria in NT-ESCs, which are
nucleus-identical to the recipient, may trigger an
adaptive alloimmune response that impairs the sur-
vival of NT-ESC grafts. The immune response is
adaptive, directed against mitochondrial content,
and amenable for tolerance induction. Mitochondrial
alloantigenicity should therefore be consideredwhen
developing therapeutic SCNT-based strategies.
In somatic cell nucleus transfer (SCNT), the nucleus of a somatic
cell is transplanted into an enucleated oocyte (Noggle et al.,
2011). It has been envisioned that by this means, autologous
pluripotent stem cells can be generated for specific patient-
matched therapies. Embryonic stem cells by nuclear transfer
(NT-ESCs) were first successfully generated from mice (Munsie
et al., 2000) and primates (Byrne et al., 2007). After substantialoptimization of the SCNT technique, the derivation of NT-ESCs
from human fetal fibroblasts (Tachibana et al., 2013), and most
recently, from adult somatic cells (Chung et al., 2014; Yamada
et al., 2014), was reported. These latter studies suggest that
age-associated changes in the nucleus donor cell are not neces-
sarily an impediment to generating human NT-ESCs (Chung
et al., 2014). Furthermore, the differentiation of insulin-producing
beta cells derived from NT-ESCs generated from a subject with
longstanding diabetes proved that specialized cell types that are
lost in diseased patients can be reestablished (Yamada et al.,
2014). Because NT-ESCs acquire healthy mitochondria from
the selected oocyte donor, inherited or acquired mtDNA dis-
eases aremost amenable for correction using the SCNT technol-
ogy (Tachibana et al., 2013). The recent advancements in SCNT
methodology have increased expectations for this approach
to lead to human-assisted reproductive technologies (Cibelli,
2014).
A so far underappreciated obstacle for clinical application of
SCNT-derived cell therapy may be the immunogenicity of mis-
matched mitochondria in NT-ESCs. After transplantation of
NT-ESC-derived cells or tissue back into the nucleus donor, mis-
matched mtDNA-coded proteins may induce alloimmunity. We
here show that allogeneic mitochondria in murine NT-ESCs
may trigger an adaptive immune response that impairs the sur-
vival of NT-ESC grafts.
To assess mitochondria-specific alloantigenicity, transplanta-
tion studies with SCNT-derived murine NT-ESCs were con-
ducted across defined immunological barriers. NT-ESCs were
produced previously by Kirak et al. (2010) using enucleated
BDF1 (B6D2F1/J) oocytes (C57BL/6J 3 DBA/2NCrl) F1 and iso-
lated BALB/c (BALB/cAnNCrl; major histocompatibility complex
[MHC] H2d) fibroblast nuclei (Figure 1A). Both oocytes and NT-
ESCs demonstrated high mitochondrial abundance (Figure S1ACell Stem Cell 16, 33–38, January 8, 2015 ª2015 Elsevier Inc. 33
Figure 1. NT-ESCs Possess Mitochondria-Related Antigenicity
(A) NT-ESCs were generated using enucleated BDF1 oocytes and isolated BALB/c fibroblast nuclei. NT-ESCs were transplanted into mitochondria-mismatched
(MM) BALB/c, MiHA-MM BDF1, MHC-MM B6, immunodeficient NOD SCID, or combined MHC-MM and mitochondria-MM CBA. See also Figure S1.
(B) Recipient-specific Th1 ELISPOT results against NT-ESCs showed significantly lower IFNg spot frequencies for BALB/c (n = 18) and BDF1 (n = 17) recipients
compared to B6 (n = 24). Overall, the CBA IFNg response (n = 15) was the strongest and the NOD SCID response (n = 6) was negligible.
(C) IL-4 (Th2) ELISPOT responses revealed similar relations among groups (BALB/c, n = 12; BDF1, n = 17; B6, n = 24; NOD SCID, n = 8; CBA, n = 10) as described
in (B) for Th1 response.
(D) The NT-ESC-specific IgM antibody production after 5 days was significantly stronger in B6 (n = 22) than in BALB/c (n = 31) or BDF1 (n = 15). No IgM antibodies
against NT-ESCs were detected in NOD SCID (n = 6).
(E) Isogeneic BALB/c ESCs (isoESCs) were transplanted either into isogeneic BALB/c or recipients with combined mitochondria- and MiHA-MM (BDF1) or
mitochondria- and MHC-MM (B6).
(F) The IFNg ELISPOT responses against isoESC grafts were negligible in BALB/c (n = 5) and significantly stronger in BDF1 (n = 22) or B6 (n = 6). Th1 activation in
MHC-MM B6 was significantly stronger than in MiHA-MM BDF1.
(G) The isoESC-specific IL-4 ELISPOT responses were significantly stronger in BDF1 (n = 23) and B6 (n = 10) than in BALB/c (n = 5).
(H) BALB/c nude mice received NT-ESC (mitochondria-MM) or isoESC grafts. Because of the T cell deficiency, the nude model assesses NK cell responses.
(I) The IFNg NK cell response against NT-ESCs (n = 9) was low, similar to the response against isoESCs (n = 8).
(J and K) Teratoma growth diagrams for NT-ESCs (J, n = 5) and isoESCs (K, n = 5) in BALB/c nudemice are shown. The overall teratoma development is depicted
in separate adjacent graphs.
On each box blot, the central mark is the median, the edges of the box are the 25th and 75th percentiles, and the whiskers extend to the most extreme data points.
MM, mismatch; *p < 0.05.
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Mitochondria Possess Alloantigenicityavailable online). The high repetition of mtDNA copies and the
high amount of mitochondrial proteins contribute to their rele-
vance as possible immunogenic antigens. Culture-expanded
NT-ESCs expressed markers related to pluripotency (Fig-
ure S1B). NT-ESCs grew tumors in immunodeficient NOD
SCID mice (NOD.CB17-Prkdcscid/J). These tumors contained
tissues of endodermal, ectodermal, and mesodermal origin (Fig-
ures S1C and S1D), thus meeting the criteria for teratomas. The
generated NT-ESCs thus contain maternally inherited C57BL/6J
(B6) mitochondria and BALB/c nuclei of the H2d haplotype. Sus-
pensions of 106 NT-ESCs were intramuscularly injected into
the thighs of recipient mice. BALB/c recipients are matched for
the entire nuclear genome but are mitochondria mismatched.34 Cell Stem Cell 16, 33–38, January 8, 2015 ª2015 Elsevier Inc.mtDNA sequence analysis comparing B6 mitochondria of the
NT-ESCs with BALB/c mitochondria revealed two nonsynony-
mous nucleotide substitutions within the mt-Co3 and mt-Cytb
genes, which resulted in amino acid substitutions in the associ-
ated proteins (Figure S2A). These two nonsynonymous single
nucleotide polymorphisms (SNPs) were therefore the only differ-
ences in the entire cellular DNA between donor cells and recip-
ient. According to dbSNP (Sherry et al., 2001), both variants
are common in mouse. The affected loci are conserved among
vertebrates (Figure S2B) and for one of the two observed variants
a human counterpart is described in dbSNP. BDF1 (H2b/d) recip-
ients share the H2d alleles with the NT-ESCs and are mitochon-
dria matched but minor histocompatibility antigen (MiHA)
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type and are therefore MHC mismatched but mitochondria
matched to the NT-ESCs. The severely immunodeficient NOD
SCID strain was used as a negative control because it cannot
mount any antigen-specific cellular immune response. The
CBA (CBA/J; H2k) strain is both MHC and mitochondria mis-
matched to the NT-ESCs. mtDNA sequencing revealed identical
mtDNA genomes for CBA and BALB/c (not shown), as was pre-
viously reported in the context of mouse mtDNA phylogeny
(Goios et al., 2007). Therefore, besides the MHC differences,
NT-ESC transplantations into BALB/c and CBA cross the same
mitochondrial mismatch.
Previous studies on the immunogenicity of murine mitochon-
drial peptides were mostly restricted to cytotoxic T lymphocytes
(CTLs) and MHC class Ia and Ib presentation (Dabhi and Lin-
dahl, 1995). We herein used assays that quantify activation of
T helper cells (Th) because this entity plays a central role in
activating CTLs and B cells, thus orchestrating graft rejection.
Five-day ELISPOT assays for Th1-specific g-interferon (IFNg)
showed a substantial immune activation in the MHC-mis-
matched B6 recipients, which was significantly stronger than
those in mitochondria-mismatched BALB/c or MiHA-mis-
matched BDF1 (Figure 1B). The MHC- and mitochondria-mis-
matched CBA strain demonstrated the highest spot frequencies
of all strains, which were approximately additive of the fre-
quencies of the isolated MHC-mismatched B6 and the isolated
mitochondria-mismatched BALB/c. The immunodeficient NOD
SCID recipients showed immunological Th1 anergy. The Th2
response, although generally generating lower IL-4 spot fre-
quencies, showed a similar relation between the recipient
strains (Figure 1C). There was also a surge in NT-ESC-specific
IgM antibodies in B6 recipients 5 days after immunization,
which was significantly stronger than that in BALB/c or BDF1
(Figure 1D). There were no NT-ESC-specific IgM antibodies in
NOD SCID.
In an additional experiment, we could exclude that there were
general differences among BALB/c, BDF1, and B6 in the degree
of immune responsiveness (Figure S2C). Splenocytes of these
three strains were unspecifically stimulated and ELISPOT assays
demonstrated similar Th1 and Th2 activation. This result permits
us to attribute the above ELISPOT results to the mismatched
proteins.
To exclude methodological bias caused by the state of
pluripotency, isogeneic BALB/c ESCs (isoESCs) were used
(Figure 1E). Transplantation experiments were performed with
fully nuclear DNA- and mtDNA-matched, isogeneic BALB/c
recipients, MiHA- and mitochondria-mismatched BDF1, and
MHC- and mitochondria-mismatched B6. There was negligible
Th1 and Th2 activation in isogeneic BALB/c recipients (Figures
1F and 1G). Between mitochondria-mismatched recipients, an
additional MHC mismatch (B6) generated a significantly stron-
ger Th1 activation than an additional MiHA mismatch (BDF1,
Figure 1F). Together, these results demonstrate that an isolated
mitochondria mismatch is sufficient to initiate marked Th acti-
vation and NT-ESC-directed antibody production. These im-
mune responses are not caused by pluripotency features
themselves. Second, an MHC mismatch causes a significantly
stronger immune activation than an MiHA mismatch, in the
setting of both additional mitochondrial match and mismatch.And third, the Th1 activation is additive for an MHC and a mito-
chondria mismatch.
Based on the results by Ishikawa (Ishikawa et al., 2010), which
assumed that the innate immunity was responsible for rejection
of mitochondria-mismatched cell grafts, the T cell-deficient
nude mouse model was used to study the NK cell response.
BALB/c nude (BALB/c nu/nu, CAnN.Cg-Foxn1 < nu > /Crl;
H2d) mice were used as recipients for either mitochondria-mis-
matched NT-ESCs or fully isogeneic isoESCs (H2d, Figure 1H).
Our results show that there was no increase in NK-cell-driven
IFNg ELISPOT frequency in response to NT-ESCs as compared
to the response to isoESCs (Figure 1I). Also, the survival of cell
grafts was similar for NT-ESCs and isoESCs and all animals
formed teratomas, thus excluding relevant innate rejection pro-
cesses (Figures 1J and 1K). Importantly, the transplantation
experiment by Ishikawa was specifically designed to be mis-
matched for the maternally transmitted mitochondrial antigen
(Mta) previously described by Fischer Lindahl (Fischer Lindahl
et al., 1980). Our transplant setting avoids this incompatibility
and, as a consequence, we did not observe relevant innate
immunity-driven rejection.
Survival of NT-ESC grafts and teratoma development were
assessed in the transplantation settings of Figure 1A. As ex-
pected, all NT-ESC transplants survived and formed teratomas
in NOD SCID recipients (Figure 2A), whereas all grafts were
rejected in fully mismatched CBAs (Figure 2B). The rather
mild Th1 activation in MiHA-mismatched BDF1 still allowed
90% teratoma development of rapidly proliferating NT-ESC
grafts (Figure 2C), whereas there was only 20% teratoma
growth in MHC-mismatched B6 (Figure 2D). In mitochondria-
mismatched BALB/c, teratomas developed in 60% of the recip-
ients, but the tumor growth was markedly slowed (Figure 2E).
Half of the tumors did not develop until day 50 to 90. Interest-
ingly, there was a strong correlation between graft survival and
Th1 activation in individual BALB/c animals (Figure 2F). Only
BALB/c recipients with very low spot frequencies developed
teratomas, whereas animals with at least moderate Th1 activa-
tion rejected their grafts. This further supports the notion of a
T cell-mediated rejection process of mitochondria-mismatched
grafts.
To confirm a mitochondrial location of the immunogenic pep-
tides, mitochondria of NT-ESCs were separated from the
remainder of the cell (cytosol) and splenocytes of NT-ESC-
immunized BALB/c were restimulated in vitro with either mis-
matched mitochondria or isogeneic cytosol (Figure 2G). Only
the mismatched mitochondria caused an IFNg response,
whereas the spot frequencies with the isogeneic cytosol frac-
tions were low, similar to those of unstimulated responder sple-
nocytes (Figure 2H). Of note, the ELISPOT frequencies of the
separated cell compartments were markedly lower than those
involving whole cells. Although their precise presentation mech-
anism remains elusive, the detection ofmitochondrial peptides in
the context of MHC (Dabhi and Lindahl, 1995; Duvvuri et al.,
2014) suggests that they enter conventional MHC antigen
presentation pathways. The dependence on indirect antigen
presentation in this assaymay explain this observation. In accor-
dancewith the ELISPOT results, in a delayed-type hypersensitiv-
ity test, only mismatched mitochondria generated paw swelling,
whereas isogeneic cytosol did not (Figure 2I). The location of theCell Stem Cell 16, 33–38, January 8, 2015 ª2015 Elsevier Inc. 35
Figure 2. The Rejection of Mitochondria-MM NT-ESCs Is Adaptive, Directed against Mitochondrial Content, and Amenable for Tolerance
Induction
(A–E) Teratoma growth diagrams for NT-ESC grafts in immunodeficient NOD SCID (A, n = 5), combined MHC- and mitochondria-MM CBA (B, n = 5), MiHA-MM
BDF1 (C, n = 10), MHC-MM B6 (D, n = 10), and mitochondria-MM BALB/c (E, n = 10) recipients. The overall teratoma development is depicted in separate
adjacent graphs. See also Figure S2.
(F) Within the BALB/c recipient group, the IFNg ELISPOT frequencies of animals that did not (no teratoma, n = 20) or did (teratoma, n = 8) show teratoma growth
were compared.
(G) BALB/c receivedmitochondria-MMNT-ESC grafts. Subsequent ELISPOT assays did not use NT-ESCs but used isolatedmitochondria or the remainder of the
cells (referred to as cytosol) for stimulation.
(H) IFNg ELISPOT analyses show some BALB/c response against isolated NT-ESC mitochondria (NT-ESCmito, n = 8), whereas no reactivity against the
mitochondria-depleted NT-ESC remnants (NT-ESCcytosol, n = 4) was detectable.
(I) There also was a paw swelling response in BALB/c recipients challenged with cutaneous injections of isolated NT-ESCmitochondria (n = 9), but not in BALB/c
challenged with the mitochondria-depleted NT-ESC remnants (n = 5).
(J) One group of BALB/cmice received their first NT-ESC grafts at neonatal stage and were reinjected during adulthood (BALB/creinject). The other group received
NT-ESC grafts only after entering adulthood (BALB/c).
(K) In ELISPOT assays, BALB/creinject (n = 14) showed a significantly lower IFNg response than BALB/c (n = 7).
(L) The overall teratoma development of NT-ESC grafts in BALB/creinject (n = 27) and BALB/c animals (n = 7) is presented.
On each box in ELISPOT blots, the central mark is themedian, the edges of the box are the 25th and 75th percentiles, and the whiskers extend to themost extreme
data points. In each scatter blot, the central mark is the mean. MM, mismatch; yp < 0.01.
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thus restricted to the mitochondrial fraction.
We next tested whether acquired immunological tolerance
against allogeneic mitochondria can be induced. In accordance
with the Medawar experiments (Billingham et al., 1953), neonatal
BALB/c mice were immunized with mitomycin-inhibited NT-
ESCs (Figure 2J). In adulthood, these animals were reinjected
with NT-ESCs (BALB/creinject). In contrast to adult BALB/c recip-
ients that received their first NT-ESC grafts, BALB/creinject
showed no IFNg response in ELISPOT assays and all animals
developed teratomas (Figures 2K and 2L). This experiment not
only shows that tolerance against allogeneic mitochondria can
reliably be induced, it is also further proof for the relevance of36 Cell Stem Cell 16, 33–38, January 8, 2015 ª2015 Elsevier Inc.the adaptive immune system in rejecting mitochondria-mis-
matched grafts.
There have been few publications on the transplantation of
mitochondria-mismatched cells or tissues with conflicting re-
sults. Although prolonged hematopoietic chimerism (Lanza
et al., 2005) and acceptance of cardiac and renal cell transplants
(Lanza et al., 2002) in cows receiving SCNT-derived mitochon-
dria-mismatched cells was reported, this may not guarantee uni-
versal success. Pigs rejected kidney grafts from SCNT-derived
mitochondria-mismatched clones (Kwak et al., 2013). In mice
and rats, it was shown that a single nonsynonymous nucleotide
substitution in the mitochondrial ND1 gene or the ATPase 6
gene, respectively, generated an aberrant peptide and resulted
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Mitochondria Possess Alloantigenicityin the loss of histocompatibility (Bhuyan et al., 1997; Davies et al.,
1991; Loveland et al., 1990). Neopeptides from human mtDNA
harboring large-scale frameshift deletions were recently re-
ported to bind to MHC molecules and can be recognized by
T cells from other individuals (Duvvuri et al., 2014). Interestingly,
the Duvvuri et al. results further suggest that some neopeptides
could bind promiscuously to both MHC class I and class II
alleles, activate CD4 and CD8 T cells, and be recognized by
CD8 memory T cells. Aberrant mitochondrial peptides may
even provoke MHC overexpression and thus amplify their immu-
nogenicity. In both mice and humans, increased MHC class I
expression in cells harboring mtDNA deletions was shown (Gu
et al., 2003). Mitochondrial peptides can thus serve as immuno-
gens (Morse et al., 1996) and the recipient immune response
may depend on the alloantigenicity of the aberrant mitochondrial
protein. Although thought to be beneficial for immune surveil-
lance and clearance of cells with mitochondrial mutations
(Duvvuri et al., 2014; Gu et al., 2003), this immune feature is
potentially hazardous in the context of SCNT-derived cell
transplantation.
Artificial reprograming using viral or nonviral plasmid-based
approaches seems to alter the expression of a multitude of
genes in induced pluripotent stem cells (iPSCs) that are differen-
tially expressed in ESCs (de Almeida et al., 2014; Zhao et al.,
2011). Specific factors being suppressed (de Almeida et al.,
2014) or overexpressed (Zhao et al., 2011) in the pluripotent state
have been suggested to contribute to the antigenicity of iPSCs.
With differentiation, the antigenicity was reported to vanish as
transcriptome profile and surface antigen expression converged
with those of corresponding somatic cells (de Almeida et al.,
2014). Terminally differentiated cells derived from iPSCs are
now believed to possess no or negligible immunogenicity (Araki
et al., 2013). The described immunogenicity is therefore differen-
tiation dependent and not due to antigenic somatic coding
mutations, which have recently been reported to occur during re-
programming (Gore et al., 2011). When compared to autologous
iPSCs that are fully matched for both nuclear and mitochondrial
DNA, NT-ESCs with mtDNA differences to the nucleus donor
possess additional allogeneic peptides that may potentially be
antigenic. These antigenic proteins inmitochondria-mismatched
NT-ESCs are maintained with differentiation and the mtDNA
copies, if anything, are increased in energy-consuming differen-
tiated cells like cardiomyocytes. However, it remains to be
determined if the results presented herein are transferrable to
differentiated cells and tissues from NT-ESCs.
The level of heterogeneity in human mitochondria is consider-
ably higher than that in laboratory mice (Goios et al., 2007);
dbSNP lists 2,066 active humanmitochondrial RefSNPs. At least
64 of these are common (global minor allele frequency 1% or
higher) and nonsynonymously coding. MT-CYTB is affected by
26 such variants andMT-CO3 by two, including the human coun-
terpart of the murine variant we observed. A recent study hints at
the level of heterogeneity in human mitochondrial genomes
(Ridge et al., 2014). Within a data set of 1,007 full mitochondrial
genomes, 899 single nucleotide variants, 26 insertions, and 20
deletions were identified. Compared to the human reference
sequence, each individual carried on average 25.3 variants. Sin-
gle individuals marked the extremes with 2 and 52 variants,
respectively.In the field of xenotransplantation, the immunity against the
aGal-antigen was long considered to be the one obstacle
that needed to be overcome to clear the path for subsequent
clinical application. However, when aGal was knocked out,
xenoimmune responses were still evident and new immune
targets surfaced that previously were overshadowed by the
strong aGal response (Miyata and Platt, 2003). Similarly,
when nuclear DNA is matched in SCNT-derived cells, antigenic
competition (Johnson et al., 1981) may allow mitochondrial
antigens to emerge as immunogens. The immunogenicity of
mitochondria should thus not be neglected when advancing
SCNT technology.
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